Daily non-political popular news in brief.

Immunosuppressive drugs are a double-edged sword to type 1 diabetics

09-04-2007 · EurekAlert!

Type 1 diabetes occurs when immune cells destroy pancreatic insulin producing beta-cells. It was hoped that islet transplantation would provide a cure for the disease, however, transplant success is short-lived and accompanied by significant side effects. New data indicate that the immunosuppressive drugs used to prevent islet transplant rejection suppress beta-cell regeneration in diabetic mice, raising the possibility that identifying immunosuppressive drugs that do not inhibit beta-cell regeneration might lead to successful regenerative islet transplantation.

Keywords: immunosuppressive, drugs, double-edged, sword, type, diabetics, drug, double, edged, diabetic

« Previous | Next »

Similar news on "Immunosuppressive drugs are a double-edged sword to type 1 diabetics":

JCI table of contents: Sept. 4, 2007
09-04-2007 · EurekAlert!
This release contains summaries, links to PDFs and contact information for the following newsworthy papers to be published Sept. 4, 2007, in the JCI, including: Immunosuppressive drugs are a double-edged sword to type 1 diabetics; It's a knock out: eIF4E-specific antisense oligonucleotides knock down cancer; New use as an anti-fungal agent for old drug; Antioxidant used in the clinic causes disease in mice; and The beta1-adrenergic receptor is two faced in the heart; and others.
Similar news · Read more »
Anemia treatment may be a double-edged sword
01-30-2008 · EurekAlert!
A study in February's Journal of Clinical Investigation finds that erythropoietin, commonly given for anemia, promotes blood-vessel growth in the eye, an effect that could either improve/worsen disease for patients with cancer, diabetic retinopathy, or retinopathy of prematurity. The effects on retinopathy depend on the timing of when erythropoietin is given.
Similar news · Read more »
OCT1 required for therapeutic effects of diabetes drug Metformin
05-01-2007 · EurekAlert!
Metformin is among the most widely prescribed drugs for the treatment of type 2 diabetes. Mouse and human studies led by Kathleen Giacomini from the University of California, San Francisco, and reported in the May 1 issue of the JCI indicate that organic cation transporter 1 is important in mediating the therapeutic effects of metformin and that genetic variation in OCT1 in diabetics may contribute to the varied patient responses to this drug.
Similar news · Read more »
Diabetes drugs increase risk of heart failure, research shows
07-27-2007 · EurekAlert!
A class of drugs commonly used to treat type 2 diabetes may double the risk of heart failure, according to a new analysis by researchers at Wake Forest University School of Medicine and colleagues.
Similar news · Read more »
New test predicts blood cancer's sensitivity to experimental cancer drug
01-22-2007 · EurekAlert!
A test developed by Dana-Farber Cancer Institute scientists is the first to identify which malignant blood cells are highly vulnerable to a promising type of experimental drugs that unleash pent-up "cell suicide" factors to destroy the cancer.
Similar news · Read more »
Trying to control pain can be a double-edged sword, say scientists
10-31-2006 · EurekAlert!
Scientists have shown for the first time why a feeling of control helps us reduce pain. The research, carried out at the Wellcome Trust Centre for Neuroimaging at UCL, London, has implications for how patients with persistent pain can cope with what is often a debilitating condition.
Similar news · Read more »
Glucose levels trigger compensation for type 2 diabetics
01-02-2007 · EurekAlert!
Many individuals with type 2 diabetes are diabetic because their body no longer responds to the hormone insulin. Before they become clinically diabetic their body tries to compensate for the lack of insulin responsiveness by increasing the mass of insulin-secreting cells (beta cells) in the pancreas. A new study shows that in mice with high-fat diet-induced insulin resistance, changes in glucose concentration are likely to be the main trigger of increased beta-cell mass.
Similar news · Read more »
Promising drug combination may help those with ocular melanoma that has spread
09-04-2007 · EurekAlert!
A combination of two drugs shows promise in treating a rare and therapy-resistant type of melanoma that originates in the eye and spreads to other organs, according to a new study led by Duke University Comprehensive Cancer Center researchers.
Similar news · Read more »
JCI table of contents: January 2, 2007
01-02-2007 · EurekAlert!
This release contains summaries, links to PDFs and contact information for the following newsworthy papers to be published January 2, 2007, in the JCI, including: Genetic mutation alters response to heart failure drugs; Glucose levels trigger compensation for type 2 diabetics; Cell relocation fixes damage to the gut lining; BCL2 reins in BIM, preventing leukemic cell death; and Complex macrophage and monocyte interactions at work in atherosclerosis.
Similar news · Read more »
Older is better -- Top-10 comparison of diabetes drugs give metformin top grade
07-24-2007 · EurekAlert!
Type 2 diabetes drug taken orally and in widespread use for more than a decade has been found to have distinct advantages over nine other, mostly newer medications used to control the chronic disease, according to a study by researchers at Johns Hopkins.
Similar news · Read more »